Allergy Therapeutics achieves solid revenue from commercial portfolio of £48.7m
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced its unaudited interim results for the six months ended 31 December 2021. · Portfolio focused